A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

ACCESS Research Site, Brooklyn

ACCESS Research Site, Albany

ACCESS Research Site, Binghamton

ACCESS Research Site, Rochester

ACCESS Research Site, Pittsburgh

ACCESS Research Site, Winchester

ACCESS Research Site, Morgantown

ACCESS Research Site, Wilmington

ACCESS Research Site, Moncks Corner

ACCESS Research Site, Chattanooga

ACCESS Research Site, Cincinnati

ACCESS Research Site, Valparaiso

ACCESS Research Site, Muncie

ACCESS Research Site, West Des Moines

ACCESS Research Site, Richfield

ACCESS Research Site, Evanston

ACCESS Research Site, Chicago

ACCESS Research Site, Chicago

ACCESS Research Site, Hazelwood

ACCESS Research Site, City of Saint Peters

ACCESS Research Site, Springfield

ACCESS Research Site, Baton Rouge

ACCESS Research Site, Norman

ACCESS Research Site, Mesquite

ACCESS Research Site, Dallas

ACCESS Research Site, Dallas

ACCESS Research Site, Shavano Park

ACCESS Research Site, Austin

ACCESS Research Site, Austin

ACCESS Research Site, West Jordan

ACCESS Research Site, Phoenix

ACCESS Research Site, Los Angeles

ACCESS Research Site, Rancho Cucamonga

ACCESS Research Site, Montclair

ACCESS Research Site, Spring Valley

ACCESS Research Site, Anaheim

ACCESS Research Site, Sacramento

ACCESS Research Site, Honolulu

ACCESS Research Site, Medford